Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC).
A case of a 32-year-old woman with mRCC is presented. These tumors could change vascularity by administration of molecular agents. We could select a drug timely based on findings of computed tomography. To our knowledge, this is the first report that tumor's character change induced by molecular targeted agents can be detected and the efficacy of molecular targeted agents can be predicted.
Written by:
Azuma T, Matayoshi Y, Sato Y, Sato Y, Nagase Y. Are you the author?
Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu, Tokyo 183-0042, Japan.
Reference: Case Rep Urol. 2012;2012:654617
doi: 10.1155/2012/654617
PubMed Abstract
PMID: 22970402
UroToday.com Renal Cancer Section
